Intrinsic resistance to MEK inhibition in kras mutant lung and colon cancer through transcriptional induction of ERBB3

Chong Sun, Sebastijan Hobor, Andrea Bertotti, Davide Zecchin, Sidong Huang, Francesco Galimi, Francesca Cottino, Anirudh Prahallad, Wipawadee Grernrum, Anna Tzani, Andreas Schlicker, Lodewyk F A Wessels, Egbert F. Smit, Erik Thunnissen, Pasi Halonen, Cor Lieftink, Roderick L. Beijersbergen, Federica DiNicolantonio, Alberto Bardelli, Livio Trusolino & 1 others Rene Bernards

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

There are no effective therapies for the ~30% of human malignancies with mutant RAS oncogenes. Using a kinome-centered synthetic lethality screen, we find that suppression of the ERBB3 receptor tyrosine kinase sensitizes KRAS mutant lung and colon cancer cells to MEK inhibitors. We show that MEK inhibition results in MYC-dependent transcriptional upregulation of ERBB3, which is responsible for intrinsic drug resistance. Drugs targeting both EGFR and ERBB2, each capable of forming heterodimers with ERBB3, can reverse unresponsiveness to MEK inhibition by decreasing inhibitory phosphorylation of the proapoptotic proteins BAD and BIM. Moreover, ERBB3 protein level is a biomarker of response to combinatorial treatment. These data suggest a combination strategy for treating KRAS mutant colon and lung cancers and a way to identify the tumors that are most likely to benefit from such combinatorial treatment.

Original languageEnglish
Pages (from-to)86-93
Number of pages8
JournalCell Reports
Volume7
Issue number1
DOIs
Publication statusPublished - Oct 4 2014

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Colonic Neoplasms
Lung Neoplasms
Phosphorylation
Receptor Protein-Tyrosine Kinases
Biomarkers
Drug Delivery Systems
Oncogenes
Drug Resistance
Tumors
Neoplasms
Proteins
Up-Regulation
Therapeutics
Cells
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Intrinsic resistance to MEK inhibition in kras mutant lung and colon cancer through transcriptional induction of ERBB3. / Sun, Chong; Hobor, Sebastijan; Bertotti, Andrea; Zecchin, Davide; Huang, Sidong; Galimi, Francesco; Cottino, Francesca; Prahallad, Anirudh; Grernrum, Wipawadee; Tzani, Anna; Schlicker, Andreas; Wessels, Lodewyk F A; Smit, Egbert F.; Thunnissen, Erik; Halonen, Pasi; Lieftink, Cor; Beijersbergen, Roderick L.; DiNicolantonio, Federica; Bardelli, Alberto; Trusolino, Livio; Bernards, Rene.

In: Cell Reports, Vol. 7, No. 1, 04.10.2014, p. 86-93.

Research output: Contribution to journalArticle

Sun, C, Hobor, S, Bertotti, A, Zecchin, D, Huang, S, Galimi, F, Cottino, F, Prahallad, A, Grernrum, W, Tzani, A, Schlicker, A, Wessels, LFA, Smit, EF, Thunnissen, E, Halonen, P, Lieftink, C, Beijersbergen, RL, DiNicolantonio, F, Bardelli, A, Trusolino, L & Bernards, R 2014, 'Intrinsic resistance to MEK inhibition in kras mutant lung and colon cancer through transcriptional induction of ERBB3', Cell Reports, vol. 7, no. 1, pp. 86-93. https://doi.org/10.1016/j.celrep.2014.02.045
Sun, Chong ; Hobor, Sebastijan ; Bertotti, Andrea ; Zecchin, Davide ; Huang, Sidong ; Galimi, Francesco ; Cottino, Francesca ; Prahallad, Anirudh ; Grernrum, Wipawadee ; Tzani, Anna ; Schlicker, Andreas ; Wessels, Lodewyk F A ; Smit, Egbert F. ; Thunnissen, Erik ; Halonen, Pasi ; Lieftink, Cor ; Beijersbergen, Roderick L. ; DiNicolantonio, Federica ; Bardelli, Alberto ; Trusolino, Livio ; Bernards, Rene. / Intrinsic resistance to MEK inhibition in kras mutant lung and colon cancer through transcriptional induction of ERBB3. In: Cell Reports. 2014 ; Vol. 7, No. 1. pp. 86-93.
@article{2cb36601d1ed4b63944fbc7d00757cbc,
title = "Intrinsic resistance to MEK inhibition in kras mutant lung and colon cancer through transcriptional induction of ERBB3",
abstract = "There are no effective therapies for the ~30{\%} of human malignancies with mutant RAS oncogenes. Using a kinome-centered synthetic lethality screen, we find that suppression of the ERBB3 receptor tyrosine kinase sensitizes KRAS mutant lung and colon cancer cells to MEK inhibitors. We show that MEK inhibition results in MYC-dependent transcriptional upregulation of ERBB3, which is responsible for intrinsic drug resistance. Drugs targeting both EGFR and ERBB2, each capable of forming heterodimers with ERBB3, can reverse unresponsiveness to MEK inhibition by decreasing inhibitory phosphorylation of the proapoptotic proteins BAD and BIM. Moreover, ERBB3 protein level is a biomarker of response to combinatorial treatment. These data suggest a combination strategy for treating KRAS mutant colon and lung cancers and a way to identify the tumors that are most likely to benefit from such combinatorial treatment.",
author = "Chong Sun and Sebastijan Hobor and Andrea Bertotti and Davide Zecchin and Sidong Huang and Francesco Galimi and Francesca Cottino and Anirudh Prahallad and Wipawadee Grernrum and Anna Tzani and Andreas Schlicker and Wessels, {Lodewyk F A} and Smit, {Egbert F.} and Erik Thunnissen and Pasi Halonen and Cor Lieftink and Beijersbergen, {Roderick L.} and Federica DiNicolantonio and Alberto Bardelli and Livio Trusolino and Rene Bernards",
year = "2014",
month = "10",
day = "4",
doi = "10.1016/j.celrep.2014.02.045",
language = "English",
volume = "7",
pages = "86--93",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - Intrinsic resistance to MEK inhibition in kras mutant lung and colon cancer through transcriptional induction of ERBB3

AU - Sun, Chong

AU - Hobor, Sebastijan

AU - Bertotti, Andrea

AU - Zecchin, Davide

AU - Huang, Sidong

AU - Galimi, Francesco

AU - Cottino, Francesca

AU - Prahallad, Anirudh

AU - Grernrum, Wipawadee

AU - Tzani, Anna

AU - Schlicker, Andreas

AU - Wessels, Lodewyk F A

AU - Smit, Egbert F.

AU - Thunnissen, Erik

AU - Halonen, Pasi

AU - Lieftink, Cor

AU - Beijersbergen, Roderick L.

AU - DiNicolantonio, Federica

AU - Bardelli, Alberto

AU - Trusolino, Livio

AU - Bernards, Rene

PY - 2014/10/4

Y1 - 2014/10/4

N2 - There are no effective therapies for the ~30% of human malignancies with mutant RAS oncogenes. Using a kinome-centered synthetic lethality screen, we find that suppression of the ERBB3 receptor tyrosine kinase sensitizes KRAS mutant lung and colon cancer cells to MEK inhibitors. We show that MEK inhibition results in MYC-dependent transcriptional upregulation of ERBB3, which is responsible for intrinsic drug resistance. Drugs targeting both EGFR and ERBB2, each capable of forming heterodimers with ERBB3, can reverse unresponsiveness to MEK inhibition by decreasing inhibitory phosphorylation of the proapoptotic proteins BAD and BIM. Moreover, ERBB3 protein level is a biomarker of response to combinatorial treatment. These data suggest a combination strategy for treating KRAS mutant colon and lung cancers and a way to identify the tumors that are most likely to benefit from such combinatorial treatment.

AB - There are no effective therapies for the ~30% of human malignancies with mutant RAS oncogenes. Using a kinome-centered synthetic lethality screen, we find that suppression of the ERBB3 receptor tyrosine kinase sensitizes KRAS mutant lung and colon cancer cells to MEK inhibitors. We show that MEK inhibition results in MYC-dependent transcriptional upregulation of ERBB3, which is responsible for intrinsic drug resistance. Drugs targeting both EGFR and ERBB2, each capable of forming heterodimers with ERBB3, can reverse unresponsiveness to MEK inhibition by decreasing inhibitory phosphorylation of the proapoptotic proteins BAD and BIM. Moreover, ERBB3 protein level is a biomarker of response to combinatorial treatment. These data suggest a combination strategy for treating KRAS mutant colon and lung cancers and a way to identify the tumors that are most likely to benefit from such combinatorial treatment.

UR - http://www.scopus.com/inward/record.url?scp=84898023140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898023140&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2014.02.045

DO - 10.1016/j.celrep.2014.02.045

M3 - Article

VL - 7

SP - 86

EP - 93

JO - Cell Reports

JF - Cell Reports

SN - 2211-1247

IS - 1

ER -